OSE Immunotherapeutics' Lung Cancer Trial Clears Second IDMC Review
Event summary
- OSE Immunotherapeutics' Phase 3 ARTEMIA trial for Tedopi® in NSCLC received a second positive recommendation from the IDMC on February 26, 2026.
- 163 patients were randomized, with 152 included in the IDMC's analysis, meeting recruitment objectives.
- The trial compares Tedopi® monotherapy with standard docetaxel in HLA-A2–positive patients with metastatic NSCLC.
- Next IDMC review is scheduled for October 2026, with study enrollment expected to conclude by year-end 2026.
- Primary endpoint results for overall survival are anticipated in Q1 2028.
The big picture
The positive IDMC recommendation for OSE Immunotherapeutics' Phase 3 ARTEMIA trial reinforces the robustness of Tedopi® as a potential new treatment for advanced NSCLC. This trial is critical in a competitive immuno-oncology space, where therapies targeting secondary resistance to immune checkpoint inhibitors are highly sought after. The continued progress of the trial could position OSE Immunotherapeutics as a key player in lung cancer treatment, pending successful outcomes and regulatory approvals.
What we're watching
- Trial Execution
- Whether the ARTEMIA trial can maintain its current pace of patient recruitment and data integrity through to completion.
- Regulatory Pathway
- How the positive IDMC recommendations will position Tedopi® for potential regulatory filings and approval.
- Competitive Dynamics
- The impact of Tedopi®'s progress on the broader NSCLC treatment landscape, particularly against established therapies like docetaxel.
Related topics